Recent Trends in Ocular Drug Delivery: Challenges and Approaches

Year : 2024 | Volume : 11 | Issue : 03 | Page : 22 38
    By

    Atharv Bhosale,

  • Atish Dabade,

  • Sarthak Khandekar,

  • Rohan Upadhye,

  1. Research Scholar, Department of Pharmacy, Dr.Shivajirao Kadam College of Pharmacy, Kasbe Digraj, Sangli, Maharashtra, India
  2. Research Scholar, Department of Pharmacy, Dr.Shivajirao Kadam College of Pharmacy, Kasbe Digraj, Sangli, Maharashtra, India
  3. Research Scholar, Department of Pharmacy, Dr.Shivajirao Kadam College of Pharmacy, Kasbe Digraj, Sangli, Maharashtra, India
  4. Research Scholar, Department of Pharmacy, Dr.Shivajirao Kadam College of Pharmacy, Kasbe Digraj, Sangli, Maharashtra, India

Abstract

Drug topically regulation can be accessed most easily in the eye. When given topically as eye drops, medication ocular bioavailability is quite low. Drug entry into specific ocular locations is complicated by the complex anatomy and physiology of the human eye. Research has long been interested in the topical administration of successful treatments. To provide a suitable ocular penetration and extend the duration of drug residence is their challenging task. Many ocular barriers, including precorneal, corneal, and blood-corneal barriers, prevent drugs from being delivered to patients effectively. These cutting-edge methods highlight the advantages of using a variety of ocular drug delivery systems, such as gels, eye ointments, intravitreal injections, prodrugs, viscosity enhancers, penetration enhancers, liposomes, niosomes, microparticles, nanosuspensions, and microemulsions. Today, the ability of nanotechnology-based carriers to bind both lipophilic and hydrophilic pharmaceuticals, improve drug stability, prolong residence time, increase bioavailability, and boost ocular permeability is what makes them appealing. Determining how the created nanocarriers will behave requires using several in vitro, ex vivo, and in vivo characterization techniques. Definition of the eye anatomy, different ocular disorders, and delivery challenges to the eyes are the goals of this review. The benefits and downsides of various ocular dosage forms and methods of administration are investigated as well. Research on ocular drug delivery that aims to provide safe sustained release of drugs in the anterior and posterior portions of the eye can benefit from the accumulated data offered in this study as a valuable source of knowledge.

Keywords: Photoreceptor, Permeability, Mucopolysaccharides, Vitreous humour, Diabetic retinopathy, Intraocular pressure, and Mucoadhesive strength.

[This article belongs to Research & Reviews: A Journal of Drug Design & Discovery ]

How to cite this article:
Atharv Bhosale, Atish Dabade, Sarthak Khandekar, Rohan Upadhye. Recent Trends in Ocular Drug Delivery: Challenges and Approaches. Research & Reviews: A Journal of Drug Design & Discovery. 2024; 11(03):22-38.
How to cite this URL:
Atharv Bhosale, Atish Dabade, Sarthak Khandekar, Rohan Upadhye. Recent Trends in Ocular Drug Delivery: Challenges and Approaches. Research & Reviews: A Journal of Drug Design & Discovery. 2024; 11(03):22-38. Available from: https://journals.stmjournals.com/rrjoddd/article=2024/view=180642


Browse Figures

References

  1. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery: an update review. Current pharmaceutical design. 2009 Aug; 15(23):003A 2724-2750.
  2. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Survey of ophthalmology. 1993 May; 37(6):435-456.
  3. Jarvinen K, Jarvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995; 16(1):3-19.
  4. Gratieri T, Gelfuso GM, Freitas O. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in-situ forming gel. Eur J Pharm Bio pharm 2011; 79(2):320-327.
  5. Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. Sustained ocular drug delivery from a temperature and pH triggered novel in-situ gel system. Drug Deliv 2007; 14 (8): 507–515.
  6. Gurny R, Ibrahim H, Buri P. The development and use of in-situ formed gels, triggered by pH. InBiopharmaceutics of ocular drug delivery 2019 Aug; 15: 81-90. CRC press.
  7. Sharma N, Bagga B, Singhal D, Nagpal R, Kate A, Saluja G, Maharana PK. Fungal keratitis: A review of clinical presentations, treatment strategies and outcomes. Ocul Surf. 2022 Apr; 24:22-30.
  8. Rouen PA, White ML. Dry Eye Disease: Prevalence, Assessment, and Management. Home Healthc Now. 2018 Mar; 36(2):74-83.
  9. Harthan JS, Opitz DL, Fromstein SR, Morettin CE. Diagnosis and treatment of anterior uveitis: optometric management. Clin Optom (Auckl). 2016 Mar; 8:23-35. https://doi.org/10.2147/OPTO.S72079
  10. Rathore KS, Nema RK. An insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res. 2009 Apr;1(1):1-5.
  11. Alonso MJ, Sanchez A. The potential of chitosan in ocular drug delivery. J pharm pharmcol 2003; 55(11):1451-1463.
  12. Li N, Zhuang C, Wang M. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 2009; 379:131-138.
  13. Zhang J, Wang S. Topical use of Coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. Int J Pharm 2009; 372(1-2): 66-75.
  14. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003; 255(1-2):13-32
  15. Genta I, Conti B, Perugini P, Pavanetto F, Spadaro A, Puglisi G. Bioadhesive microspheres for ophthalmic administration of acyclovir. J Pharm Pharmacol 1997; 49(8):737-742.
  16. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Survey of ophthalmology. 1993 May; 37(6):435-456.
  17. Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects- and update Pharm Pharmacol 2001; 53(8):1047-1067.
  18. Limpeanchob N, Tiyaboonchai W, Lamlertthon S, Viyoch J, Jaipan S. Efficacy and toxicity of amphotericin B-chitosan nanoparticles in mice with induced systemic candidiasis. Naresuan University Journal: Science and Technology (NUJST). 2006; 14(2):27-34.
  19. Nagpal K, Singh SK, Mishra DN. Chitosan Nanoparticles: A Promising System in Novel Drug Delivery. Chem Pharm Bull 2010; 58(11):1423-1430.
  20. De Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. International journal of pharmaceutics. 2001 Aug 14;224(1-2):159-68.
  21. De Campos, A.M., Diebold, Y., Carvalho, E.L.S. et al. Chitosan Nanoparticles as New Ocular Drug Delivery Systems: in Vitro Stability, in Vivo Fate, and Cellular Toxicity. Pharm Res 21, 803–810 (2004). https://doi.org/10.1023/B:PHAM.0000026432.75781.cb.
  22. Shinde UA, Shete JN, Nair HA, Singh KH. Design and characterization of chitosan-alginate microspheres for ocular delivery of azelastine. Pharmaceutical development and technology. 2014 Nov; 19(7):813-823.
  23. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in-situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. Journal of controlled release. 1997 Feb; 44(2-3):201-208.
  24. Zatz JL, Knapp S. Viscosity of xanthan gum solution at low shear rates. J Pharm Sci 1984; 73(4): 468-471.
  25. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 2006; 1(2):117-128.
  26. Rupenthal ID, Green CR, Alany RG. Comparison of ion-activated in-situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in-vitro International journal of pharmaceutics. 2011 Jun; 411(1-2):69-77.
  27. Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery. Journal of Controlled Release. 2020 Dec; 328:895-916.
  28. Jansson PE, Lindberg B. Structural studies of gellan gum, an extracellular polysaccharide elaborated by Pseudomonas elodea. Carbohydrate Research 1983; 124(1):135-139.
  29. Thanou M, Verhoef JC, Marbach P. Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatisation analogue in-vitro and in-vivo. J Pharm Sci 2000; 89 (7): 951–957.
  30. Di Colo G, Zambito Y, Burgalassi S. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int J Pharm 2004; 273(1-2):37-44.
  31. Liu Y, Liu J, Zhang X, Zhang R, Huang Y, WU C. In-situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery. AAPS Pharm SciTech 2010 Jun;11:610-20.
  32. Taghe S, Mirzaeei S. Preparation and characterization of novel, mucoadhesive ofloxacin nanoparticles for ocular drug delivery. Brazilian Journal of Pharmaceutical Sciences. 2019 Aug 15;55. https://doi.org/10.1590/s2175-97902019000117105
  33. Moris ER, Foster TJ. Role of conformation in synergistic interactions of xanthan. Carbohydrate Polymer 1994; 23(2):133-135.
  34. Kuo MS, Mort AJ, Dell A. Identification and location of L-glycerate, an unusual acyl substituent in gellan gum. Carbohydrate Research 1986; 156:173-187.
  35. Pszczola DE. Gellan gum wins IFT’s food technology industrial achievement award. Food Technology. 1993;47(9):94-6.
  36. Chandrasekaran R, Puigjaner LC, Joyce KL, Arnott S. Cation interactions in gellan: an-X-ray study of the potassium salt. Carbohydrate Research 1988; 181:23-40.
  37. Balasubramaniam J, Kant S, Pandit JK. In-vitro and In-vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin. Acta Pharm 2003; 53(4):251-262.
  38. Gupta H, Velpandian T, Jain S. Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery. J Drug Targeting 2010; 18(7):499-505.
  39. Balasubramaniam J, Pandit JK. Ion-activated in-situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv 2003; 10(3):185–191.
  40. Ramaiah S, Kumar TP, Ravi V. Studies on biopolymers for ophthalmic drug delivery. Journal of Macromolecular Science, Part A: Pure and Applied Chemistry. 2007 Feb; 44(2):229-234.
  41. Ceulemans J, Vinckier I, Ludwig A. The use of xanthan gum in ophthalmic dosage form: rheological characterisation of the insteraction with mucin. J Pharm Sci 2002; 91(4):1117-1127.
  42. Talukdar MM, Kinget R. Comparative study on xanthan gum and hydroxypropylmethyl cellulose as matrices for controlled-release drug delivery. II. Drug diffusion in hydrated matrices. International journal of pharmaceutics. 1997 May 12;151(1):99-107.
  43. Zirnsak MA, Boger DV, Tirtaatmadja V. Study shear and dynamic rheological properties of xanthan gum solution in viscous solvents. J Rheol 1999; 43(3):627-650.
  44. Dodi G, Pala A, Barbu E, Peptanariu D, Hritcu D, Popa MI, Tamba BI. Carboxymethyl guar gum nanoparticles for drug delivery applications: preparation and preliminary in-vitro investigations. Materials Science and Engineering: C. 2016 Jun; 63:628-636.
  45. Soumya RS, Ghosh S, Abraham ET. Preparation and characterization of guar gum nanoparticles. International journal of biological macromolecules. 2010 Mar; 46(2):267-269.
  46. Abdelkader H, G Alany R. Controlled and continuous release ocular drug delivery systems: pros and cons. Current drug delivery. 2012 Jul; 9(4):421-430.
  47. Kumar S, Issarani R, Nagori BP, Ahuja M. Design and evaluation of guar gum-based ofloxacin sustained release ocular insert. Asian Journal of Pharmaceutics. 2012 Jun; 6(3):198-203.
  48. Shirakawa M, Yamatoya K, Nishinari K. Tailoring of xyloglucan properties using an enzyme. Food hydrocolloids. 1998 Jan 1;12(1):25-8.
  49. Freitas RA, Martin S, Santos G L, Valenga F, Buckeridge M S, Reicher F. Physico-chemical properties of seed xyloglucans from different sources. Carbohydrate Polymers 2005; 60(4):507–514.
  50. Burgalassi SL, Raimondi R, Pirisino G, Banchelli E, Boldrini, and Saettone MF.Effect of xyloglucan (tamarind seed polysaccharide) on conjunctiva cell adhesion to laminin and on corneal epithelium wound healing. Eur J Ophthalmol 2000; 10(1):71–76.
  51. Ghelardi EA, Tavanti F, Celandroni A, Lupetti C, Blandizzi E, BoldriniM, Campa, and Senesi Effect of a novel mucoadhesive polysaccharide obtained from tamarind seeds on the intraocular penetration of gentamicinand ofloxacin in rabbits. J Antimicrobial Chemotherapy 2000; 46(5):831–834.
  52. Verma D, Sharma SK. Recent advances in guar gum-based drug delivery systems and their administrative routes. International Journal of Biological Macromolecules. 2021 Jun 30; 181:653-671.
  53. Noreen S, Ghumman SA, Batool F, Ijaz B, Basharat M, Noureen S, Kausar T, Iqbal S. Terminalia arjuna gum/alginate in-situ gel system with prolonged retention time for ophthalmic drug delivery. International journal of biological macromolecules. 2020 Jun; 152:1056-1067.
  54. Rao PS, Ghosh TP, Krishna S. Extraction and purification of tamarind seed polysaccharide. J Sci Ind Research 1946; 4:705.
  55. Goyal P, Kumar V, Sharma P. Carboxymethylation of tamarind kernel powder. Carbohydrate Polymer 2007; 69(2):251-255.
  56. Ghelardi E, Tavanti A, Davini P, Celandroni F, Salvetti S, Parisio E. A mucoadhesive polymer extracted from Tamarind seed improves the intraocular penetration and efficacy of Rufloxacin in Topical treatment at Experimental Bacterial Keratitis. Antimicro Agents Chem 2004; 48(9):3396-3401.
  57. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment of sodium-hyaluranate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002; 86(2):181-184.
  58. Condon PI, McEwen CG, Wright M, Mackintosh G,  Prescott RJ, McDonald C. Double blind, randomised, placebo controlled, crossover, multicenter study to determine the efficacy of a 0.1%(w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol 1999; 83(10):1121-1124.
  59. Lin J, Wu H, Wang Y, Lin J, Chen Q, Zhu X. Preparation and ocular pharmacokinetics of hyaluronic acid-modified mucoadhesive liposomes. Drug Delivery. 2016 May; 23(4):1144-1151.
  60. Mahajan HS, Deshmukh SR. Development and evaluation of gel-forming ocular films based on xyloglucan. Carbohydrate polymers. 2015 May 20; 122:243-247.
  61. Vijaya C, Goud KS. Ion-activated in-situ gelling ophthalmic delivery systems of azithromycin. Indian journal of pharmaceutical sciences. 2011 Nov; 73(6):615.
  62. Guillaumie F, Furrer P, Felt-Baeyens O, Fuhlendorff BL, Nymand S, Westh P, Gurny R, and Schwach-Abdellaoui K. Comparative studies of various hyaluronic acids produced by microbial fermentation for potential topical ophthalmic applications. J Biomed Mater Res 2010; 92(4):1421-1430.
  63. Zeng W, Li Q, Wan T, Liu C, Pan W, Wu Z, Zhang G, Pan J, Qin M, Lin Y, Wu C. Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability. Colloids and Surfaces B: Biointerfaces. 2016 May; 141:28-35.
  64. Al-Saedi ZH, Alzhrani RM, Boddu SH. Formulation and in-vitro evaluation of cyclosporine-An inserts prepared using hydroxypropyl methylcellulose for treating dry eye disease. Journal of Ocular Pharmacology and Therapeutics. 2016 Sep; 32(7):451-462.
  65. Donnenfeld, E. D., Holland, E. J., Durrie, D. S., & Raizman, M. B. (2007). Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. Advances in Therapy, 24(4), 852–862.
  66. P., YEN S. F., Ophthalmic compositions comprising chitosan and active substance in particular Ketotifen, and use there for the treatment of ocular allergic conditions. (2022),W0 02/100376 A1, 1-21.
  67. Khare A, Singh I, Pawar P, Grover K. Design and evaluation of voriconazole loaded solid lipid nanoparticles for ophthalmic application. Journal of drug delivery. 2016;2016(1):6590361. https://doi.org/10.1155/2016/6590361
  68. Thakur G, Singh A, Singh I. Chitosan-montmorillonite polymer composites: formulation and evaluation of sustained release tablets of aceclofenac. Scientia pharmaceutica. 2016; 84(4):603-18.
  69. Bao Z, Yu A, Shi H, Hu Y, Jin B, Lin D, Dai M, Lei L, Li X, Wang Y. Glycol chitosan/oxidized hyaluronic acid hydrogel film for topical ocular delivery of dexamethasone and levofloxacin. International journal of biological macromolecules. 2021 Jan; 167:659-66.
  70. Toda IN, Shinozaki. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjogren’s syndrome. Cornea 1996; 15(2):120-128.
  71. Donshik PC, Nelson JD, Abelson M, McCulley JP, Beasley C, Laibovitz RA. Effectiveness of BION tears, Cellufresh, Aquasite, and Refresh Plus for moderate to severe dry eye. InLacrimal Gland, Tear Film, and Dry Eye Syndromes 2: Basic Science and Clinical Relevance 1998 Jan 1 (pp. 753-760). Boston, MA: Springer US.
  72. Tundisi LL, Mostaço GB, Carricondo PC, Petri DF. Hydroxypropyl methylcellulose: Physicochemical properties and ocular drug delivery formulations. European Journal of Pharmaceutical Sciences. 2021 Apr; 159:105736. https://doi.org/10.1016/j.ejps.2021.105736
Regular Issue Subscription Review Article
Volume 11
Issue 03
Received 18/10/2024
Accepted 22/10/2024
Published 02/11/2024
264


My IP

PlumX Metrics